Literature DB >> 2537040

Clearance function of type C receptors of atrial natriuretic factor in rats.

F A Almeida1, M Suzuki, R M Scarborough, J A Lewicki, T Maack.   

Abstract

The overwhelming majority of atrial natriuretic factor (ANF) receptors in kidney and vascular tissues do not mediate any of the known functional effects of the hormone. To test whether these receptors (C-ANF receptors) function as clearance receptors for circulating ANF-(1-28), we determined the effects of C-ANF-(4-23) [des[Gln18Ser19Gly20Leu21Gly22]rANF-(3-23)-NH2], a specific ligand of C-ANF receptors, on the pharmacokinetics and hydrolysis of 125I-labeled ANF-(1-28) in anesthetized rats. Radioactivity in plasma was characterized by trichloroacetic acid solubility and high-pressure liquid chromatography. C-ANF-(4-23) (1 and 10 micrograms.min-1.kg body wt-1) led to marked dose-dependent increases in initial plasma concentration of administered 125I-ANF-(1-28) and decreases in its volume of distribution at steady state (Vss), metabolic clearance rate (MCR), and appearance of hydrolytic products ([125I]monoiodotyrosine and free 125I) in plasma (Pm). At the highest dose, C-ANF-(4-23) decreased Vss from 97 +/- 12 to 36 +/- 2 ml/100 g body wt, MCR from 50 +/- 4 to 12 +/- 1 ml.min-1.100 g body wt-1, and Pm from 54 +/- 8 to 11 +/- 2% of initial plasma 125I-ANF-(1-28). The data demonstrate that C-ANF receptors are mainly responsible for the very large volume of distribution and fast MCR of ANF in the rat. In this manner, C-ANF receptors are likely to play an important role in the homeostasis of circulating ANF.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537040     DOI: 10.1152/ajpregu.1989.256.2.R469

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  28 in total

Review 1.  Therapeutic use of atrial natriuretic factor.

Authors:  J M Connell; A G Jardine; D B Northridge
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

2.  Novel analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats.

Authors:  H Jin; B Li; B Cunningham; J Tom; R Yang; P Sehl; G R Thomas; A Ko; D Oare; D G Lowe
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

3.  Raised plasma levels of atrial natriuretic factor in cardiac allograft recipients: evidence of increased cardiac secretion and decreased renal clearance.

Authors:  C C Lang; T Moreland; A M Choy; T H Pringle; G P McNeill; A D Struthers
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 4.  Natriuretic peptide metabolism, clearance and degradation.

Authors:  Lincoln R Potter
Journal:  FEBS J       Date:  2011-04-07       Impact factor: 5.542

5.  Characterization of neutral endopeptidase 24.11 in dog glomeruli.

Authors:  C Landry; P Santagata; W Bawab; M C Fournié-Zaluski; B P Roques; P Vinay; P Crine
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

6.  Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the rat.

Authors:  M R Wilkins; S L Settle; J E Kirk; S A Taylor; K P Moore; R J Unwin
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

7.  Effects of the neutral endopeptidase inhibitor, SQ 28,603, on regional haemodynamic responses to atrial natriuretic peptide or proendothelin-1 [1-38] in conscious rats.

Authors:  S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

Review 8.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

9.  Receptors for atrial natriuretic peptide are decreased in the kidney of rats with streptozotocin-induced diabetes mellitus.

Authors:  L A Sechi; J P Valentin; C A Griffin; E Lee; E Bartoli; M H Humphreys; M Schambelan
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

10.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.